NCT03036943 (FRONTIER) is a NA clinical trial of Fluciclovine in Breast Cancer, sponsored by University of Oxford.

Who is sponsoring NCT03036943?

NCT03036943 is sponsored by University of Oxford.

What drugs are being tested in NCT03036943?

Interventions in NCT03036943: Fluciclovine.

What condition does NCT03036943 study?

NCT03036943 studies Breast Cancer.

Is NCT03036943 still recruiting?

NCT03036943 is currently completed. Last updated 19 December 2018.

Last reviewed 2018-12-19 · How we verify

NCT03036943: FRONTIER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluciclovine (18F) Imaging of Breast Cancer

Completed NA Last updated 19 December 2018

What this trial tests

NA trial testing Fluciclovine in Breast Cancer in 40 participants. Completed in 4 December 2018.

Timeline

15 February 2017

Primary endpoint
4 December 2018

4 December 2018

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	15 February 2017
Primary completion	4 December 2018
Estimated completion	4 December 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

Fluciclovine — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

University of Oxford

Who can join

40 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out what a new amino acid-based PET agent, fluciclovine (18F), can tell us about breast cancer biology (how it grows and develops), and quantify the differences in fluciclovine (18F) uptake between breast cancer subtypes. This will inform further work to investigate its use in breast cancer management.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Window of opportunity clinical trial designs to study cancer metabolism.
Aroldi F, Lord SR. · · 2020 · cited 19× · PMID 31819180 · DOI 10.1038/s41416-019-0621-4
Characterising <sup>18</sup>F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
Scott NP, Teoh EJ, Flight H, Jones BE, et al · · 2022 · cited 6× · PMID 34795409 · DOI 10.1038/s41416-021-01623-3

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03036943 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 19 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03036943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing